An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Latest Information Update: 27 Oct 2025
At a glance
- Drugs PGN-EDODM1 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions
- Acronyms FREEDOM-OLE
- Sponsors PEPGENE
Most Recent Events
- 27 Oct 2025 New trial record